%PDF-1.3
%
8 0 obj
<>>>/BBox[0 0 612 792]/Length 132>>stream
xA =eGmz. 656'Z4#CAϢ(QzWG3 D"ɒdaNqAΙY)rC#0Ƅե-ql1p?Q-[?'8
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 132>>stream
xA =eGmz. 656'Z4#CAϢ(QzWG3 D"ɒdaNqAΙY)rC#0Ƅե-ql1p?Q-[?'8
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 132>>stream
xA =eGmz. 656'Z4#CAϢ(QzWG3 D"ɒdaNqAΙY)rC#0Ƅե-ql1p?Q-[?'8
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 132>>stream
xA =eGmz. 656'Z4#CAϢ(QzWG3 D"ɒdaNqAΙY)rC#0Ƅե-ql1p?Q-[?'8
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 132>>stream
xA =eGmz. 656'Z4#CAϢ(QzWG3 D"ɒdaNqAΙY)rC#0Ƅե-ql1p?Q-[?'8
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 132>>stream
xA =eGmz. 656'Z4#CAϢ(QzWG3 D"ɒdaNqAΙY)rC#0Ƅե-ql1p?Q-[?'8
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 132>>stream
xA =eGmz. 656'Z4#CAϢ(QzWG3 D"ɒdaNqAΙY)rC#0Ƅե-ql1p?Q-[?'8
endstream
endobj
10 0 obj
<>stream
Arbortext Advanced Print Publisher 9.0.114/W
2021-01-19T11:22:35-08:00
2021-01-06T12:12:39+05:30
application/pdf
LRB-2020-0069-ver9-Kim_2P 1..7
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
uuid:13881612-1073-467b-a363-26a8aae913a8
uuid:89be74de-d7dd-4295-9569-2b9cbce614a3
endstream
endobj
11 0 obj
<>stream
x+ |
endstream
endobj
12 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
19 0 obj
<>stream
x+ |
endstream
endobj
20 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
21 0 obj
<>stream
x+ |
endstream
endobj
22 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
23 0 obj
<>stream
x+ |
endstream
endobj
24 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
26 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(fu)20.9(nc)19.7(ti)20.6(on)-221.1(an)19.7(d)-237.2(c)0(a)24.3(u)0(s)21(e)-238.4(ps)21(yc)19.7(ho)20.8(lo)26.5(gi)20.7(ca)18.5(l)-237.4(d)0(i)20.7(s)0(t)20.9(r)0(e)25.5(s)0(s)15.5(,)-233.8(le)19.6(a)15(d)0(i)20.7(n)0(g)-226.8(t)0(o)-227(i)16.1(mp)19.6(ai)19.5(re)19.7(d)]TJ
0 -1.1174 TD
[(qu)20.8(al)19.5(it)20.6(y)-196.9(o)0(f)-186.5(l)0(i)26.3(f)0(e)19.7(.)-199.3(To)-187.7(pr)20.9(ev)25.4(en)19.7(t)-197.1(t)0(h)20.7(e)-198.1(pr)20.9(og)20.8(re)19.7(ss)21.2(io)20.7(n)-196.9(o)0(f)-186.5(t)0(h)26.5(e)-198.1(di)20.7(se)19.9(as)19.9(e)-198.1(a)0(n)19.7(d)-196.9(it)20.6(s)]TJ
0 -1.1116 TD
[(co)19.7(mp)19.6(l)16.1(i)0(c)19.6(a)0(t)19.5(i)0(o)20.7(n)0(s)21(,)-400.8(ea)18.5(rl)20.7(y)-404.3(d)0(e)25.4(t)0(e)19.6(c)0(t)19.5(i)0(o)20.7(n)-404.3(an)25.4(d)-404.3(m)0(a)18.4(n)0(a)19.7(g)0(e)25.4(m)0(e)18.4(n)0(t)-394(o)0(f)-388.1(l)0(y)20.7(m)0(p)19.6(h)0(e)19.7(-)]TJ
T*
[(de)19.7(ma)-258(ar)19.7(e)-267.2(i)0(m)19.5(p)0(o)20.8(r)0(t)20.7(a)0(n)19.7(t)0(.)]TJ
1.0137 -1.1116 TD
[(Because)-232.1(it)-232.8(is)-232.5(a)-226.9(rare)-237.1(complication,)-229.2(previous)-234.5(publications)-234.7(on)]TJ
-1.0137 -1.1174 TD
[(lymphedema)-356.9(among)-347.7(patients)-356.9(treated)-351.2(with)-351.1(mTOR)-354.3(inhibitors)]TJ
0 -1.1116 TD
[(have)-271.7(generally)-278.6(been)-271.7(case)-278.4(reports.)]TJ
7.3823 0 0 6.5614 193.7196 663.7605 Tm
(1,712)Tj
9.843 0 0 9.843 216.7369 659.3951 Tm
[(The)-270.6(reported)-276.1(patients)]TJ
-15.7182 -1.1116 TD
[(were)-405(diagnosed)-398.1(with)-403(mTOR)-400.4(inhibitor-related)-408.8(lymphedema)]TJ
0 -1.1174 TD
[(after)-422.6(discontinuation)-422.5(of)-422.6(the)-419.3(medication)-425.1(and)-419.2(observing)-419.9(im-)]TJ
0 -1.1116 TD
[(provement.)-276.2(Recently,)-270.5(Fourgeaud)-277(et)-268.4(al.)-271.9(described)-278.2(the)-269.5(clinical)]TJ
T*
[(features)-305.9(and)-298.2(outcomes)-306.1(of)-301.7(lymphedema)-305.1(among)-301.6(patients)-299.3(trea-)]TJ
0 -1.1174 TD
[(ted)-200.4(with)-201.4(SRL.)]TJ
7.3823 0 0 6.5614 116.1071 608.9951 Tm
(13)Tj
9.843 0 0 9.843 125.4614 604.5731 Tm
[(They)-202.6(reported)-201.3(that)-201.7(patients)-207.2(required)-201.3(complex)]TJ
-6.4451 -1.1116 TD
[(decongestive)-369.3(therapy)-361.5(\(CDT\))-365.6(for)-360.3(the)-361.7(lymphedema,)-366.1(but)-360.5(they)]TJ
T*
[(did)-279.9(not)-279.9(report)-284.3(CDT)-282.9(outcomes.)]TJ
1.0137 -1.1116 TD
[(The)-230.3(use)-228.9(of)-226.8(mTOR)-233.4(inhibitors)-230.2(is)-232.5(increasing)-233.4(as)-227.8(the)-229.2(frequency)]TJ
-1.0137 -1.1174 TD
[(of)-324.7(organ)-329.2(transplantation)-331.5(is)-330.4(increasing)-331.3(and)-327(more)-329.3(new)-327.9(cancer)]TJ
0 -1.1116 TD
[(treatment)-222.3(regimens)-213.9(include)-217.6(mTOR)-216.1(inhibitors.)-216.3(As)-216(a)-215.4(result,)-218.6(the)]TJ
T*
[(incidence)-677.2(of)-676.1(lymphedema)-673.7(among)-676(patients)-679.5(treated)-673.8(with)]TJ
0 -1.1174 TD
[(mTOR)-291(inhibitors)-293.5(is)-290.1(also)-293.5(increasing,)-294.4(although)-292.5(this)-286.7(complica-)]TJ
0 -1.1116 TD
[(tion)-436.6(remains)-437.4(rare)-438.6(in)-440.1(absolute)-437.4(terms.)-437.5(Physicians)-439.3(should)-438.5(be)]TJ
T*
[(aware)-320.9(of)-313.2(the)-315.6(characteristics)-323.1(of)-318.9(lymphedema)-316.6(among)-318.9(patients)]TJ
0 -1.1174 TD
[(taking)-480.3(mTOR)-486.8(inhibitors,)-481.3(and)-482.5(the)-482.6(complication)-485(should)-478.8(be)]TJ
0 -1.1116 TD
[(managed)-415.6(by)-411.1(either)-418.1(stopping)-412.1(the)-413.5(medication)-413.5(or)-411.1(prescribing)]TJ
T*
[(CDT.)-338.1(This)-339.6(study)-333.7(aimed)-337.5(to)-336.4(investigate)-338.5(the)-338.7(characteristics)-346.1(of)]TJ
0 -1.1174 TD
[(lymphedema)-310.9(among)-313.2(patients)-310.8(treated)-310.9(with)-310.8(mTOR)-314(inhibitors.)]TJ
0 -1.1116 TD
[(In)-411.1(addition,)-417(we)-413.2(aimed)-418.1(to)-411.3(delineate)-418.1(CDT)-415.3(outcomes)-415.5(among)]TJ
T*
[(patients)-282(maintained)-286.8(on)-278.7(mTOR)-285.2(inhibitors.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 415.8991 Tm
(Methods)Tj
/F9 1 Tf
0 -1.8336 TD
[(Study)-332.3(design)-336.6(and)-335.7(participants)]TJ
/F5 1 Tf
9.843 0 0 9.843 72 383.0172 Tm
[(We)-397.3(retrospectively)-395.8(reviewed)-399.2(the)-396.3(medical)-398.6(records)-395.7(of)-393.8(pa-)]TJ
-1.0137 -1.1174 TD
[(tients)-284.4(who)-286.4(visited)-279.8(the)-286.8(lymphedema)-287.8(clinic)-280(of)-284.4(the)-286.8(Department)]TJ
0 -1.1116 TD
[(of)-451.4(Rehabilitation)-458.5(Medicine)-457(of)-451.4(Asan)-455.5(Medical)-455.9(Center)-453.6(from)]TJ
T*
[(March)-256.4(2016)-257.8(to)-250(December)-263.2(2019.)-255.5(This)-253.2(study)-258.9(was)-252.8(approved)-258.8(by)]TJ
T*
[(the)-188.9(governing)-189.7(institutional)-194.7(review)-194.2(board)-185.2(\(IRB\))-191.8(of)-192.2(our)-187.6(hospital)]TJ
0 -1.1174 TD
[(\(IRB)-323.2(No.)-323.3(2019-1472\).)-319.7(During)-324.4(the)-321.4(period)-324.7(under)-323.4(study,)-319.9(there)]TJ
0 -1.1116 TD
[(were)-209.2(27)-209.5(patients)-212.9(who)-205.8(underwent)-214.8(organ)-208.2(transplantation)-216.3(before)]TJ
T*
[(lymphedema)-259(developed,)-258.9(among)-255.6(whom,)-251.9(21)-255.6(were)-255.2(treated)-259.1(with)]TJ
0 -1.1174 TD
[(mTOR)-342.8(inhibitors)-333.9(and)-338.5(included)-339.7(in)-336.4(the)-338.7(study.)-342.9(The)-334(remaining)]TJ
25.504 43.6701 TD
[(six)-504.3(patients)-500.9(were)-502.9(not)-498.8(taking)-497.6(mTOR)-498.3(inhibitors)-500.9(and)-499.8(were,)]TJ
0 -1.1174 TD
[(therefore,)-448.8(excluded.)-447.8(We)-443.4(identied)-444.4(an)-441.1(additional)-445.8(three)-439.9(pa-)]TJ
0 -1.1116 TD
[(tients)-336.3(with)-333.8(advanced)-341.8(breast)-331.4(cancer)-339.5(who)-332.5(developed)-336.1(lymphe-)]TJ
T*
[(dema)-278.7(after)-278.6(an)-274.1(EVL)-277.3(clinical)-277.8(trial.)-275.4(Finally,)-271.7(we)-280.7(enrolled)-276.3(a)-273(total)]TJ
T*
[(of)-186.5(24)-186.5(patients)-189.9(with)-184.1(lymphedema)-189.9(after)-186.4(using)-184(mTOR)-187.3(inhibitors.)]TJ
1.0137 -1.1174 TD
[(To)-279.9(nd)-273.8(out)-279.9(the)-275.3(unique)-278.6(characteristics)-288.5(of)-278.6(mTOR)-279.4(inhibitor-)]TJ
-1.0137 -1.1116 TD
[(related)-236.1(lymphedema)-230.2(by)-226.8(analyzing)-226.8(lower)-232.3(extremity)-232.7(computed)]TJ
T*
[(tomography)-313(venography)-312.8(\(LE)-310.9(CTV\),)-310.4(we)-309.5(set)-309.7(up)-313.2(a)-307.5(case)-313(group)]TJ
0 -1.1174 TD
[(\(mTOR)-228.7(inhibitor-related)-230.2(lymphedema,)-227.9(lymphedema)-224.4(patients)]TJ
0 -1.1116 TD
[(using)-299.2(mTOR)-296.7(inhibitors\))-294.6(and)-298.2(a)-296(control)-291.3(group)-299.2(\(cancer-related)]TJ
T*
[(lymphedem)-9.1(a,)-316.7(lymphedema)-322.4(patients)-322.4(not)-320.2(using)-322.2(mTOR)-319.8(inhib-)]TJ
0 -1.1174 TD
[(itors\))-300.4(for)-291.2(comparison.)-300.1(There)-297(were)-295.6(seven)-295.6(patients)-299.3(in)-290.3(the)-298.3(case)]TJ
0 -1.1116 TD
[(group,)-417.8(who)-418.9(underwent)-422.2(LE)-413.5(CTV.)-418.8(We)-420.3(enrolled)-420.3(seven)-416.6(age-,)]TJ
T*
[(gende)-7.8(r-,)-282(lymphedema)-293.6(site-,)-286.6(and)-286.7(stage-matched)-292.1(patients)-293.6(who)]TJ
T*
[(were)-324.4(not)-314.5(using)-322.2(mTOR)-319.8(inhibitors,)-320(had)-315.5(lower)-318.7(extremity)-324.9(lym-)]TJ
0 -1.1174 TD
[(phede)-7.8(ma,)-365.1(and)-367.3(underwent)-370.3(LE)-361.7(CTV)-369.3(from)-368.4(the)-367.5(same)-364.9(lymphe-)]TJ
0 -1.1116 TD
[(dema)-284.4(clinic)-285.8(in)-278.8(the)-281.1(same)-284.2(period)-278.6(of)-284.4(time)-277.8(as)-285.4(a)-278.7(case)-284.2(group.)]TJ
/F9 1 Tf
8.9663 0 0 8.9663 313.0582 519.9872 Tm
[(Comprehensive)-337(review)]TJ
/F5 1 Tf
9.843 0 0 9.843 323.0361 503.5463 Tm
[(We)-598.9(comprehensively)-598.4(reviewed)-600.8(clinical)-600.3(characteristics,)]TJ
-1.0137 -1.1116 TD
[(imaging)-252.3(studies,)-248.3(and)-240.6(CDT)-248.3(outcomes.)-251.9(Captured)-248.4(clinical)-249(char-)]TJ
0 -1.1174 TD
[(acteristics)-258.8(included)-253.3(age,)-251(gender,)-254.2(body)-246.3(mass)-254.1(index,)-252.1(transplant)]TJ
0 -1.1116 TD
[(organ,)-660.9(type)-656.5(of)-658.8(mTOR)-653.8(inhibitor,)-658.9(dose)-656.2(and)-661.1(duration)-655.3(of)]TJ
T*
[(mTOR)-527.1(inhibitor,)-526.4(lymphedema)-524(site,)-521.7(and)-522.8(clinical)-531.2(stage)-520.4(of)]TJ
T*
[(lymphedem)-9.1(a.)-241.8(Lymphedema)-248.6(was)-247.1(diagnosed)-248.3(based)-243.8(on)-244.1(clinical)]TJ
0 -1.1174 TD
[(evalu)-8(ation)-490.7(and)-494(lymphoscintigraphy.)-499.4(The)-495.2(clinical)-496.6(stage)-491.6(of)]TJ
0 -1.1116 TD
[(lymphedem)-9.1(a)-319(was)-321.9(determined)-327(according)-324.5(to)-319.1(the)-321.4(International)]TJ
T*
[(Society)-355.7(of)-347.7(Lymphology)-353.4(\(ISL\))-352(criteria.)]TJ
7.3823 0 0 6.5614 467.5463 420.2645 Tm
(14)Tj
9.843 0 0 9.843 478.3747 415.8991 Tm
[(We)-351.2(also)-351.1(identied)]TJ
-16.7953 -1.1174 TD
[(accompany)-10(ing)-279.9(disease)-281.6(and)-280.9(cellulitis)-284.6(history.)]TJ
1.0137 -1.1116 TD
[(We)-420.3(reviewed)-428(medical)-421.6(imaging)-419.3(studies)-423.4(for)-417.9(patients)-426(who)]TJ
-1.0137 -1.1116 TD
[(were)-220.7(examined)-215.3(by)-209.5(lymphoscintigraphy)-219.5(or)-209.5(LE)-211.9(CTV.)-217.2(We)-213(mea-)]TJ
0 -1.1174 TD
[(sured)-329(the)-327.1(total)-323.8(cross-sectional)-331.9(area)-324.6(\(CSA\))-329.7(of)-324.7(the)-321.4(mid-thigh,)]TJ
0 -1.1116 TD
[(along)-381.2(with)-379.9(its)-383.5(muscular)-380.9(and)-378.8(subcutaneous)-385.1(fat)-378.9(components)-8.8(,)]TJ
T*
[(using)-293.4(ImageJ,)-295.6(version)-296.8(1.49)-289(K)-289.9(\(National)-295.7(Institutes)-294.5(of)-295.9(Health,)]TJ
T*
[(Bethesda,)-414.1(MD\),)-411.7(which)-410.9(distinguished)-413(muscle)-413.3(and)-407.6(fat)-413.5(using)]TJ
0 -1.1174 TD
[(Houns)-7.1(eld)-465.4(units)]TJ
7.3823 0 0 6.5614 380.0692 332.5605 Tm
(1517)Tj
9.843 0 0 9.843 403.1432 328.1952 Tm
[(\(Fig.)-474.3(1\).)-466.4(The)-472.2(mid-thigh)-472.3(\(equidistant)]TJ
-9.1522 -1.1116 TD
[(from)-466.3(the)-465.4(femoral)-472.1(head)-467.5(and)-465.2(medial)-465.4(femoral)-466.4(condyle\))-466.3(was)]TJ
T*
[(chosen)-216.1(for)-210.6(the)-211.9(single-slice)-212.6(image)-216.5(because)-213.8(it)-209.8(is)-209.5(the)-211.9(region)-215.2(with)]TJ
0 -1.1174 TD
[(the)-286.8(highest)-279.6(muscle)-280.8(mass.)]TJ
7.3823 0 0 6.5614 412.1006 299.6787 Tm
(18)Tj
ET
q
1 i
127.049 277.398 m
487.162 277.398 l
487.162 93.26 l
127.049 93.26 l
W n
q
360.113 0 0 184.139 127.049 93.26 cm
/Im1 Do
Q
Q
BT
/F6 1 Tf
9.845 0 0 9.845 62.022 76.5354 Tm
[(FIG.)-400.1(1.)]TJ
/F5 1 Tf
4.1807 0 TD
[(Measuring)-397.9(subcutaneous)-401(fat)-401.7(and)-401.5(muscle)-401(using)-396.5(mid-thigh)-396.4(computed)-403.2(tomography)-398.2(venography)-398.1(images.)-404.4(\(1\))-400.3(Sub-)]TJ
-4.1807 -1.0135 TD
[(cutaneous)-300.3(fat)-303.8(in)]TJ
/F10 1 Tf
6.7548 0 TD
(red)Tj
/F5 1 Tf
1.3302 0 TD
[(.)-302.8(HU,)-294.9(190)-302.4(to)-301.6(30.)-299(We)-299(excluded)-299.5(the)]TJ
/F10 1 Tf
14.1142 0 TD
[(red)-297.7(area)]TJ
/F5 1 Tf
3.7661 0 TD
[(within)-301(muscle)-297.4(and)-303.6(bone)-298.8(marrow.)-300.4(\(2\))-302.4(Muscle)-302.8(in)]TJ
/F10 1 Tf
19.4524 0 TD
(red)Tj
/F5 1 Tf
1.336 0 TD
[(.)-297.1(HU,)-300.7(0)]TJ
-46.7536 -1.0135 TD
[(100.)-334.6(We)-333.6(excluded)]TJ
/F10 1 Tf
7.7683 0 TD
[(red)-338(area)]TJ
/F5 1 Tf
3.8352 0 TD
[(of)-336(skin.)-329.8(HU,)-335.2(Hounseld)-339(units.)-331(Color)-334.4(images)-337.7(are)-333.6(available)-336.6(online.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(2)Tj
49.2744 0 TD
[(KIM)-330.4(ET)-338.7(AL.)]TJ
ET
endstream
endobj
29 0 obj
<>stream
Adobe d
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz m !1AQa"q2#BRbr3$4CS%cs5DT
&6E'dtU7()euFVfvGWgw8HXhx9IYiy*:JZjz ? hu<٤Y a
s$4i @X0OMpѬttV[W GQ/("R {dz̚Ziij,˪j<^EzoQE,4[hdUK8(Lxre xr|U/'|qpJkwadޅ,*fD @vWa/=7MFH1y`'<}AڀHjP/OrJ3@A@.@)-"0&BۭͤCd
Dq*LӈլzqzXL-fTGNiD#tּѭ/9K=H,Ҵ[Ix>c~Wr$y-o[ݛyHKjb*=G䮷fƔȅ6V5+hV6/¿.$ƜYj>-ۚc>dcQhݧa/zNGəY N@kME(.ď"2\DUdc+
ĺ7pLEq$tp4)jX8iEs\v~]]E?JƦHMTr;`?V^ krG
"il7H⼟Zu7Q@Ӌ_iicgı\OwRԥ